Literature DB >> 26590662

Neuro-oncology dilemma: Tumour or tumefactive demyelinating lesion.

Mohammad Abdoli1, Mark S Freedman2.   

Abstract

Tumefactive demyelinating lesions (TDLs) are not an uncommon manifestation of demyelinating disease but can pose diagnostic challenges in patients without a pre-existing diagnosis of multiple sclerosis (MS) as well as in known MS patients. Brain tumours can also arise in MS patients and can be seen in chronic MS patients as co-morbidities. Delayed diagnosis or unnecessary intervention or treatment will affect the ultimate prognosis of these patients. In this article, we will review some typical cases illustrating the dilemma and review the information that helps to differentiate the two conditions. The intention is not to present an extensive differential diagnosis of both entities, but to examine some typical examples when the decision arises to decide between the two. We take a somewhat different approach, by presenting the cases in "real time", allowing the readers to consider in their own minds which diagnosis they favour, discussing in detail some of the pertinent literature, then revealing later the actual diagnosis. We would urge readers to consider re-visiting their first thoughts about each case after reading the discussion, before reading the follow-up of each case. The overall objective is to highlight the real possibility of being forced to decide between these two entities in clinical practise, present a reasonable approach to help differentiate them and especially to focus on the possibility of TDLs in order to avoid unnecessary biopsy.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain tumour mimics; Comorbidity in MS; Multiple sclerosis; Tumefactive demyelinative lesions-TDLs

Mesh:

Year:  2015        PMID: 26590662     DOI: 10.1016/j.msard.2015.07.013

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  12 in total

1.  A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?

Authors:  Afsaneh Shirani; Gregory F Wu; Caterina Giannini; Anne H Cross
Journal:  BMJ Case Rep       Date:  2018-06-28

2.  Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study.

Authors:  Carlotta Chiavazza; Angelina Cistaro; Piercarlo Fania; Antonio Bertolotto; Paola Cavalla; Roberta Rudà; Lorenzo Pinessi; Riccardo Soffietti
Journal:  Neurol Sci       Date:  2016-07-25       Impact factor: 3.307

3.  The landscape of brain tumor mimics in neuro-oncology practice.

Authors:  Lalanthica V Yogendran; Tuba Kalelioglu; Joseph H Donahue; Haroon Ahmad; Kester A Phillips; Nicole M Calautti; Maria-Beatriz Lopes; Ashok R Asthagiri; Benjamin Purow; David Schiff; Sohil H Patel; Camilo E Fadul
Journal:  J Neurooncol       Date:  2022-07-20       Impact factor: 4.506

Review 4.  Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.

Authors:  Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt
Journal:  Kidney Int       Date:  2017-04-20       Impact factor: 10.612

5.  Using germline variants to estimate glioma and subtype risks.

Authors:  Jeanette E Eckel-Passow; Paul A Decker; Matt L Kosel; Thomas M Kollmeyer; Annette M Molinaro; Terri Rice; Alissa A Caron; Kristen L Drucker; Corinne E Praska; Melike Pekmezci; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Bradley J Erickson; Claudia F Lucchinetti; Joseph L Wiemels; John K Wiencke; Melissa L Bondy; Beatrice Melin; Terry C Burns; Caterina Giannini; Daniel H Lachance; Margaret R Wrensch; Robert B Jenkins
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 13.029

6.  Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Theodore Argyrakos; Georgios Koutsis; Maria-Eleptheria Evangelopoulos; Elisabeth Andreadou; Maria Anagnostouli; Marianthi Breza; John S Tzartos; Elias Gialafos; Antonios N Dimitrakopoulos; Georgios Velonakis; Panagiotis Toulas; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

7.  Joint approach of diffusion- and perfusion-weighted MRI in intra-axial mass like lesions in clinical practice simulation.

Authors:  Ra Gyoung Yoon; Ho Sung Kim; Gil Sun Hong; Ji Eun Park; Seung Chai Jung; Sang Joon Kim; Jeong Hoon Kim
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

Review 8.  Biomarkers in Rare Demyelinating Disease of the Central Nervous System.

Authors:  Marina Boziki; Styliani-Aggeliki Sintila; Panagiotis Ioannidis; Nikolaos Grigoriadis
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

9.  Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma.

Authors:  Heath David French
Journal:  Surg Neurol Int       Date:  2021-05-03

Review 10.  Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.

Authors:  Aigli G Vakrakou; Maria-Evgenia Brinia; Ioanna Svolaki; Theodore Argyrakos; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.